3.1 Formulary Management & Utilization Management Controls

3.1 Formulary Management & Utilization Management Controls

In third-party pharmacy benefit administration, the formulary serves as the central clinical and financial blueprint governing drug coverage. A formulary is an evidence-based, continually updated list of prescription medications approved for reimbursement by a health plan, Pharmacy Benefit Manager (PBM), or health system. Formularies are designed to steer prescribing toward clinically effective, safe, and cost-efficient therapies.

To balance quality healthcare delivery with escalating pharmaceutical expenditures, payers implement Utilization Management (UM) controls. Pharmacy technicians must master formulary architectures, tiered cost-sharing models, UM restriction rules, and exception pathways to assist patients when claims trigger coverage edits at the point of sale.

+-----------------------------------------------------------------------------+
|                   THE 6-TIER FORMULARY BENEFIT SPECTRUM                     |
|                                                                             |
|   LOWEST PATIENT COST                                  HIGHEST PATIENT COST |
|   [Tier 6] ---> [Tier 1] ---> [Tier 2] ---> [Tier 3] ---> [Tier 4] ---> [Tier 5]|
|   Select Care  Preferred   Non-Pref.   Preferred   Non-Pref.   Specialty /  |
|   Preventive   Generic     Generic     Brand       Brand       Biologics    |
|   ($0 Copay)   ($0-$10)    ($10-$25)   ($30-$50)   ($75-$120)  (25%-33% Co.)|
+-----------------------------------------------------------------------------+

---

1. The Pharmacy and Therapeutics (P&T) Committee

The composition and operational integrity of every formulary is governed by a Pharmacy and Therapeutics (P&T) Committee. Operating within PBMs, commercial health plans, state Medicaid agencies, and hospital health systems, the P&T committee is an advisory group of practicing physicians, clinical pharmacists, pharmacoeconomic analysts, and medical ethicists.

Core Responsibilities of the P&T Committee

• Clinical Evaluation: Reviews comparative clinical trial literature, Food and Drug Administration (FDA) approvals, and clinical practice guidelines to determine drug safety and therapeutic efficacy.
• Pharmacoeconomic Analysis: Assesses Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA), balancing drug acquisition costs, manufacturer rebates, and downstream healthcare cost offsets (e.g., prevented hospitalizations).
• Formulary Placement & Tier Assignment: Assigns medications to specific coverage tiers and designates clinical utilization restrictions.
• Quarterly Reviews & Safety Updates: Meets at least quarterly to evaluate newly approved molecular entities, expanded FDA indications, new generic market entries, and FDA Black Box Warnings or drug safety communications.

---

2. Formulary Structural Models

Health plans deploy different formulary models based on client employer preferences, market competition, and regulatory mandates:

+-----------------------------------------------------------------------------+
|                        FORMULARY STRUCTURAL DESIGNS                         |
|                                                                             |
|   [OPEN FORMULARY]     -> All FDA drugs covered; variable tiered copays     |
|   [CLOSED FORMULARY]   -> Only listed drugs covered; unlisted pay $0        |
|   [VALUE-BASED / INCENTIVE] -> Heavy cost-sharing differentials drive choice|
|   [NEGATIVE LIST]      -> Explicit exclusions (cosmetic, fertility, DESI)   |
+-----------------------------------------------------------------------------+

Open Formulary

• Mechanics: The payer covers virtually all FDA-approved prescription drugs. While all medications receive coverage, the plan uses differential copayments across tiers to encourage generic and preferred brand selection.
• Access: Offers maximum prescribing flexibility with minimal point-of-sale claim rejections for non-coverage.

Closed Formulary

• Mechanics: The health plan covers only specific medications explicitly listed on the formulary. If a physician prescribes a drug omitted from the list (a non-formulary drug), the electronic claim rejects immediately with NCPDP Reject 70 (Product/Service Not Covered - Non-Formulary).
• Reimbursement: The plan pays $0 unless the prescriber successfully files and wins a formal Non-Formulary Exception based on medical necessity.

Value-Based / Tiered Incentive Formulary

• Mechanics: Employs multi-tier cost-sharing differentials to align patient financial incentives with clinical value. Highly cost-effective first-line medications receive low copayments, whereas high-cost medications with lower comparative value require substantial patient cost-sharing.

Negative Formularies & Excluded Drug Classes

• Mechanics: Payers publish explicit lists of excluded products that are statutorily or contractually barred from coverage under any circumstances, including:
  1. Cosmetic and Lifestyle Agents: Topical tretinoin for photoaging, hair loss treatments (finasteride for alopecia), and depigmenting agents.
  2. Fertility Medications: Gonadotropins, clomiphene (unless the employer group elects an optional fertility rider).
  3. Weight Loss / Anti-Obesity Agents: Statutorily excluded from standard Medicare Part D coverage.
  4. DESI Drugs: Products identified under the FDA Drug Efficacy Study Implementation (DESI) as lacking substantial evidence of effectiveness.
  5. Over-the-Counter (OTC) Drugs: Except when specifically mandated by the Affordable Care Act (ACA) or state Medicaid policies.

---

3. The 6-Tier Formulary Architecture

Modern commercial and Medicare Part D plans predominantly utilize a 6-Tier Formulary Architecture to structure patient cost-sharing:

---

4. Utilization Management (UM) Mechanisms

Utilization Management controls are automated clinical rules embedded within PBM claims adjudication engines. When an adjudicated prescription triggers a UM rule, the claim rejects with a specific NCPDP reject code, requiring administrative or clinical intervention.

+-----------------------------------------------------------------------------+
|                      UTILIZATION MANAGEMENT (UM) GATES                      |
|                                                                             |
|   [Rx Submitted] ---> [1. Formulary Check]  (Covered / Excluded)            |
|                              |                                              |
|                              v                                              |
|                       [2. Age/Gender Check] (Demographic restrictions)      |
|                              |                                              |
|                              v                                              |
|                       [3. Step Therapy]     (Prior trial of 1st-line drug)  |
|                              |                                              |
|                              v                                              |
|                       [4. Quantity Limits]  (Max dose / days supply)        |
|                              |                                              |
|                              v                                              |
|                       [5. Prior Auth (PA)]  (Clinical criteria review)      |
|                              |                                              |
|                              v                                              |
|                       [PAID CLAIM ADJUDICATED]                              |
+-----------------------------------------------------------------------------+

1. Step Therapy (Fail-First Protocols)

• Operational Concept: Requires the patient to first try and fail one or more lower-cost, clinically proven first-line medications (usually Tier 1 or Tier 2 generics) before the plan will approve coverage for a higher-cost second-line or brand therapy (Tier 3 or Tier 4).
• Electronic Adjudication Check: The PBM adjudication engine automatically scans the patient's electronic pharmacy claims history over a designated lookback window (typically 90 to 180 days). If evidence of the prerequisite drug is found in the claims history, the claim automatically processes as paid. If no claims record exists, the transaction rejects with NCPDP Reject 75 (Prior Authorization Required), typically accompanied by a step-therapy-specific reject message.
• Clinical Example: A patient prescribed a brand-name SGLT2 inhibitor for glycemic control must show a prior claim for generic metformin unless a documented contraindication (e.g., renal impairment) is verified.

2. Quantity Limits (QL)

• Operational Concept: Restricts the maximum physical amount of medication dispensed per prescription transaction or over a defined timeframe. Quantity limits prevent medication stockpiling, curb potential abuse or diversion, and align dispensing with FDA-approved dosing parameters.
• Categories of Quantity Limits:
  1. Daily Dose Caps: Limits the maximum number of dosage units per 24-hour period (e.g., maximum 2 tablets of zolpidem 10 mg per day; maximum 9 tablets of sumatriptan 100 mg per 30 days).
  2. Days Supply Maximums: Restricts retail dispensing to a 30-day supply for specialty medications or Schedule II controlled substances, while permitting 90-day supplies for maintenance drugs through mail order or preferred retail networks.
  3. Unit-of-Use Constraints: Enforces package size rules for non-breakable dosage units, such as insulin pens (e.g., 5 pens = 15 mL box), topical creams (e.g., 45 g tube), or ophthalmic drops (e.g., 5 mL bottle).
• Rejection Coding: Triggers NCPDP Reject 76 (Plan Limitations Exceeded) or NCPDP Reject 75.

3. Age and Gender Restrictions

• Operational Concept: Ensures medications are dispensed only to patient demographics matching FDA clinical indications.
• Examples:
  • Topical Retinoids (e.g., tretinoin): Covered automatically for patients under age 35 for acne vulgaris; requires PA for patients aged 35 and older to prevent non-covered cosmetic use for wrinkle reduction.
  • Phosphodiesterase-5 Inhibitors (e.g., sildenafil, tadalafil): Restricted to pulmonary arterial hypertension (PAH) under Revatio/Adcirca brand names; restricted from coverage for erectile dysfunction under standard Part D formularies.
• Rejection Coding: Triggers NCPDP Reject 60 (Product/Service Not Covered For Patient Age) or NCPDP Reject 61 (Product/Service Not Covered For Patient Gender).

4. Morphine Milligram Equivalent (MME) Safety Edits

• Operational Concept: Implemented pursuant to Centers for Disease Control and Prevention (CDC) opioid prescribing guidelines and CMS Part D safety mandates to curb opioid overutilization, overdose risk, and concurrent respiratory depression.
• CMS / CDC Opioid Safety Thresholds:
  • 7-Day Supply Cap for Opioid-Naive Patients: Restricts first-time opioid prescriptions (no opioid claim in the prior 60-90 days) for acute pain to a maximum 7-day supply.
  • 50 MME/Day Cumulative Soft Safety Edit: Alerts the dispensing pharmacist to review total opioid load across concurrent prescriptions; pharmacist can override after clinical review using Submission Clarification Codes.
  • 90 MME/Day Cumulative Hard Safety Edit: Triggers an immediate point-of-sale claim rejection requiring formal Prior Authorization or prescriber clinical attestation before the prescription can be dispensed.
  • Concurrent Opioid-Benzodiazepine Safety Edit: Rejects claims when a patient is concurrently prescribed an opioid and a benzodiazepine due to life-threatening respiratory depression risks.

Mathematical Formulation: Daily MME Calculation

To calculate total daily MME, multiply the total daily dosage of the prescribed opioid in milligrams by its established CDC MME conversion factor:

$\text{Total Daily MME} = \sum_{i=1}^{n} \Big( \text{Daily Dose of Opioid}_i \text{ (mg)} \times \text{MME Conversion Factor}_i \Big)$

$\text{Daily Dose (mg)} = \text{Strength per Unit (mg)} \times \left( \frac{\text{Quantity Dispensed}}{\text{Days Supply}} \right)$

Practical MME Calculation Example

A patient presents two concurrent opioid prescriptions for a 30-day supply:

1. Oxycodone 10 mg tablets: 1 tablet TID (#90 tablets for 30 days).
2. Morphine ER 15 mg tablets: 1 tablet BID (#60 tablets for 30 days).

Step 1: Calculate daily dose for Oxycodone: $\text{Daily Dose} = 10 \text{ mg} \times 3 = 30 \text{ mg/day}$ $\text{Oxycodone MME} = 30 \text{ mg} \times 1.5 = 45 \text{ MME/day}$

Step 2: Calculate daily dose for Morphine ER: $\text{Daily Dose} = 15 \text{ mg} \times 2 = 30 \text{ mg/day}$ $\text{Morphine MME} = 30 \text{ mg} \times 1.0 = 30 \text{ MME/day}$

Step 3: Calculate cumulative daily MME: $\text{Cumulative MME} = 45 \text{ MME/day} + 30 \text{ MME/day} = \mathbf{75 \text{ MME/day}}$

Clinical Result: The 75 MME/day cumulative load exceeds the 50 MME/day soft edit threshold (requiring pharmacist clinical review and DUR override) but remains below the 90 MME/day hard edit threshold.

---

5. Formulary Exception Pathways

When a patient cannot take a formulary preferred drug or requires coverage for an off-formulary product, the prescriber may file a formal Formulary Exception Request with the PBM:

+-----------------------------------------------------------------------------+
|                     FORMULARY EXCEPTION TYPES & RULES                       |
|                                                                             |
|   [TIERING EXCEPTION]                                                       |
|   - Request lower cost-sharing tier for an already covered drug             |
|   - Move Tier 4 Non-Preferred Brand down to Tier 3 Preferred Brand copay    |
|   - EXCEPTION RULE: Cannot tier down from Tier 5 Specialty Tier (CMS rules) |
|                                                                             |
|   [NON-FORMULARY EXCEPTION]                                                 |
|   - Request coverage for a drug completely omitted/excluded from formulary  |
|   - Requires proof that all formulary alternatives are ineffective/harmful  |
|   - If approved, drug is typically covered at Tier 4 cost-sharing           |
+-----------------------------------------------------------------------------+

Tiering Exception

• Definition: A request to obtain a covered non-preferred drug at the lower cost-sharing tier assigned to preferred alternative medications.
• Clinical Justification Required: The prescriber must document that all preferred alternatives on the lower tier have been tried and failed, are clinically contraindicated, or caused severe adverse reactions.
• Specialty Tier Limitation: Under CMS Medicare Part D regulations, plan sponsors are prohibited from granting tiering exceptions to lower the cost-sharing of medications placed on Tier 5 (Specialty Tier). Specialty biologics cannot be tiered down to generic or preferred brand copay levels.

Non-Formulary Exception

• Definition: A request to obtain benefit coverage for a prescription drug that is omitted from the plan's closed formulary.
• Clinical Justification Required: The prescriber must submit supporting clinical chart notes certifying that all formulary alternatives are ineffective, unsafe, or medically inappropriate for the patient's specific clinical condition.
• Adjudication Outcome: If approved, the off-formulary drug is covered, typically adjudicating at the Tier 4 (Non-Preferred Brand) cost-sharing level.